Owkin, a predictive analytics company that utilizes machine learning and artificial intelligence for drug discovery and development, has raised a $11 million Series A funding round. The investment was led by Otium Venture, with participation from Cathay Innovation, Plug and Play, and NJF Capital.

Bruno Raillard, partner at Otium Venture, will join Owkin’s board.

[Image courtesy: Owkin]